Related Experiment Video
Updated: Aug 17, 2026
09:26
The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse
Published on: May 16, 2016
[Arthritic pathogenicity of Mycoplasma and Mycoplasma arthritis in humans]
Vestnik Akademii Meditsinskikh Nauk SSSR
|January 1, 1991
Abstract:
The review deals with Mycoplasma-induced arthritis. It provides the author's own results and the data available in the literature, which suggest that "arthritogenic" Mycoplasma make an etiological contribution to the development of human rheumatic arthritis. It also discusses some well-known and hypothetic mechanisms responsible for the pathogenesis of Mycoplasma-induced arthritis.
Insights
Mycoplasma bacteria may cause human rheumatic arthritis. This review explores the evidence and potential mechanisms behind Mycoplasma-induced arthritis.
Area of Science:
- Rheumatology
- Microbiology
- Immunology
Context:
- Mycoplasma are bacteria implicated in various human diseases.
- Arthritis is a common condition affecting joints.
- The role of Mycoplasma in rheumatic arthritis is under investigation.
Purpose:
- To review the evidence linking Mycoplasma to human rheumatic arthritis.
- To discuss the pathogenesis of Mycoplasma-induced arthritis.
- To present author's results and literature data on the topic.
Summary:
- "Arthritogenic" Mycoplasma strains are suggested to be etiological agents in human rheumatic arthritis.
- The review covers author's findings and existing literature.
- Potential mechanisms of Mycoplasma-induced arthritis pathogenesis are discussed.
Impact:
- This review consolidates current knowledge on Mycoplasma-induced arthritis.
- It highlights the potential role of specific Mycoplasma in rheumatic diseases.
- Understanding these mechanisms may lead to new diagnostic or therapeutic strategies.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...